100 results about "Dna complex" patented technology

Modified DNA polymerases have an affinity for DNA such that the polymerase has an ability to incorporate one or more nucleotides into a plurality of separate DNA templates in each reaction cycle. The polymerases are capable of forming an increased number of productive polymerase-DNA complexes in each reaction cycle. The modified polymerases may be used in a number of DNA sequencing applications, especially in the context of clustered arrays.

Disclosed are methods and systems for determining the three-dimensional structure of chromatin in eukaryotic cells. More specifically, disclosed are methods and systems for obtaining chromatin structural information by surface immobilization, i.e tethering crosslinked protein:DNA complexes and/or ligated DNA complexes to media such as beads, gels, and or matrices during the conformation capture assay. In general, the method includes contacting a cell with a cross-linking reagent to cross-link DNA and protein in the cell; lysing the cell, producing cross-linked protein:DNA complexes by cutting the chromatin using a chemical, physical or enzymatic method, substantially immobilizing the cross-linked protein:DNA complexes, ligating the cross-linked protein:DNA complexes intramolecularly such that the ligated protein:DNA complexes represent structural organization of the chromatin; characterizing the ligated DNA by sequencing or other methods; and identifying any structural organization of the chromatin. The structural organization preferably includes information relating to interacting loci of the chromatin.

The present invention discloses a novel quinobenzoxazine self-assembly complex on DNA and on the topoisomerase II-DNA complex. The related model is used to design a new series of quinobenzoxazines, pyridobenzophenoxazines, pyrridonaphthophenoxazines, and other related compounds that may exhibit anticancer or antibiotic activity. The anticancer activity of these compounds is thought to operate via stabilization of the topoisomerase II-DNA complex and/or interaction with G-quadruplexes, while the antibiotic activity of these compounds derives from their ability to inhibit gyrase, the bacterial type II topoisomerase.

Modified DNA polymerases have an affinity for DNA such that the polymerase has an ability to incorporate one or more nucleotides into a plurality of separate DNA templates in each reaction cycle. The polymerases are capable of forming an increased number of productive polymerase-DNA complexes in each reaction cycle. The modified polymerases may be used in a number of DNA sequencing applications, especially in the context of clustered arrays.

Poly(ester-anhydrides) or polyesters formed from ricinoleic acid and natural fatty diacids and their method of preparation and its use for delivering bioactive agents including small drug molecules, peptides and proteins, DNA and DNA complexes with cationic lipids or polymers or nano and microparticles loaded with bioactive agents are disclosed herein. The drug delivery compositions are administered to a patient in a liquid form, increase in viscosity in vivo to form a drug depot or implant, and are able to release the incorporated bioactive agent for weeks. In the preferred embodiment, the drug delivery formulations are administered by injection. In one embodiment, the compositions are suitable for local or regional delivery of drugs to diseased sites, such as treating solid tumors and bone infections. In a preferred embodiment, the drug delivery compositions are suitable for site-specific chemotherapy for the treatment of solid tumors including: squamous cell carcinoma (SCC) of the head and neck, prostate cancer, and sarcomas for intratumoral injection or insertion.

Embodiments disclosed herein relate to a method of detecting specific DNA sequences and the application of this method in the detection of pathogens, viruses, drug-resistant pathogens, genomic variations associated with disease/disorder susceptibility etc. based on specific signature sequences unique to the pathogens, viruses, drug-resistant pathogens or genomic variations. The method can also be used to distinguish a pool of same-sized dsDNA on the basis of sequence differences. The method uses non-optically labeled bis-PNA and/or gamma-PNA probes to tag specific target sequences for identification by solid-state nanopores.

The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.

The invention belongs to the technical field of biological detection, and particularly relates to a novel protein-DNA complex for detecting a carcino-embryonic antigen as well as a synthetic method and application thereof. The novel protein-DNA complex comprises a horseradish peroxidase-marked carcino-embryonic antigen secondary antibody, glucose oxidase and a DNA structure. The novel protein-DNAcomplex structure encapsulated with a great amount of enzyme-labeled secondary antibodies and glucose oxidase is established on the basis of a rolling circle replication technology and is used as enzyme cascade signal amplification probe. A 96-pore plate is used for fixing carcino-embryonic antigen monoclonal antibody molecules, after the to-be-detected carcino-embryonic antigen is added, a sandwiched structure is formed. The encapsulated glucose oxidase is used for catalyzing the glucose to be oxidized to generate H2O2, then the H2O2 is catalyzed by virtue of the horseradish peroxidase to oxidize ABTS, so that the high-sensitivity and high-specificity colorimetry detection of the carcino-embryonic antigen can be realized, and the novel protein-DNA complex has important significance for the early diagnosis and clinical research of cancers.

The invention provides a [12] aneN3 cationic lipid containing a targeted group and a fluorescent group and a transgenic vector containing the same. The invention also discloses preparation methods of the cationic lipid and the transgenic vector. The cationic lipid provided by the invention contains the targeted group cholic acid and the fluorescent group naphthalimide simultaneously; the transgenic vector formed by the cationic lipid has lower cytotoxicity, has a certain targeting property on hepatoma cells, not only can monitor intracellular transport and release of vector/DNA complexes in a same cell but also has a certain selectivity on the hepatoma cells to promote the development of gene therapy, and also has higher transfection efficiency; the preparation methods of the cationic lipid and the transgenic vector are simple, mature, and easy to control.

Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.

Cyanines which selectively bind to G-quadruplex DNA complexes, particularly quadruplexes expressed in cancer cells, and methods of making and using thereof are described herein. The cyanine can be a symmetrical or unsymmetrical streptocyanine, hemicyanine, closed chain cyanine, or combinations thereof. The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine and/or inhibit binding of the cyanine to duplex DNA. One or more of the cyanines can be formulated with one or more pharmaceutical excipients and/or carrier to prepare pharmaceutical compositions suitable for administration to a patient, particular a human patient. The compounds and compositions described herein can be used to treat diseases or disorders characterized by the expression of G-quadruplex DNA, such as cancer.

The invention discloses a method for enhancing proliferation and post-transplantation survival ability of adipose derived stem cells. TGF-[beta]1 at a special concentration is added to culture of the adipose derived stem cells, and the TGF-[beta]1, after binding with a TGF-[beta]II type receptor (TGF-[beta]RII), activates and recruits TGF-[beta]I receptor (TGF-[beta]RI) composition so as to form a receptor complex in the form of a dimer. The TGF-[beta]RII can phosphorylate a glycine-serine enriched region (GS sequence) of the TGF-[beta]RI and activate serine/threonine activity of the TGF-[beta]RI. The activated TGF-[beta]RI can phosphorylate receptor related smad2 and smad3 proteins, and then the smad2/smad3 form a complex and further bind with smad4; the formed complex is transferred into cell nucleus; the smad3 and the smad4 are bound to a DNA sequence called SBE, while the smad2 reacts with the DNA complex through an interaction with the smad4, so that the expression of an ECM synthetic gene is activated. The proliferation of the adipose derived stem cells, which are processed by virtue of the method provided by the invention, is accelerated and the post-transplantation survival ability is enhanced.

Compositions, methods, and kits for detecting DNA topoisomerase II-DNA complexes are disclosed.

Disclosed are the three-dimensional structures of two complexes: a Cabin1/MEF2B/DNA complex and a MITR/MEF2B/DNA complex. Also disclosed are methods of using such structures and models derived therefrom in structure-based design methods to identify regulators of the interaction of MEF2 with its cognate ligands/corepressors, to compounds that can be designed or identified based on the knowledge of such structures and models, and to methods of using such compounds in therapeutic methods. Also disclosed are peptide and non-peptide regulatory compounds that regulate, and preferably inhibit, MEF2.

The invention belongs to the field of nucleic acid detection, in particularly relates to a reagent kit and a method for bidirectional signal amplification detection on miRNA [micro-RNA (ribonucleic acid)]. The reagent kit comprises first DNA (deoxyribonucleic acid) probes (1) with hairpin structures, second DNA probes (2) with hairpin structures and annular DNA probes (3). The first DNA probes with the hairpin structures can be paired with alkali bases of the miRNA, so that the hairpin structures can be opened; the second DNA probes with the hairpin structures and the miRNA can be competitively bound with the first DNA probes with the hairpin structures, so that the miRNA can be released; a DNA complex formed by the second DNA probes with the hairpin structures and the first DNA probes with the hairpin structures is provided with at least sticky end; continuous alkali groups of a section of each annular DNA probe are complementary to the corresponding sticky end of the DNA complex, and rolling cycle amplification can be carried out by the annular DNA probes and the DNA complex to obtain G quadruplex amplification products. The reagent kit and the method have the advantages that the miRNA can be measured by the aid of the reagent kit and the method, and the reagent kit is easy and convenient to operate, low in cost, high in sensitivity and good in specificity.

The invention discloses a modifying glassy carbon electrode with a carbon nanotube-DNA complex, a preparation method and an application thereof. The modifying glassy carbon electrode with the carbon nanotube-DNA complex is formed by coating a carbon nanotube-DNA complex film at the outside of a glassy carbon electrode substrate. The process of the preparation method is that a carbon nanotube and water solution of single stranded DNA which only contains G and T are mixed to prepare carbon nanotube-DNA mixed liquid, the carbon nanotube-DNA solution is prepared by the ultrasonic breaking mixed treatment and the centrifugal separation, the powder carbon nanotube-DNA complex is obtained by freeze drying, and the modifying glassy carbon electrode with the carbon nanotube-DNA is prepared by coating the carbon nanotube-DNA complex film formation on the glassy carbon electrode. The prepared modifying glassy carbon electrode with the carbon nanotube-DNA has application in the detection of the concentration of hydrogen peroxide solution. The preparation method has the advantage that the preparation process is simple, which is particularly easy to realize the detection of the concentration of the hydrogen peroxide solution in a biological body.

Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.

The present invention is based, in part, on the discovery of the human-specific regulatory control of cGAS and the structure of the active human cGAS-DNA complex, as well as compositions comprising the modified hcGAS polypeptide, hcGAS-DNA complex, hcGAS-DNA-ATP complex, and methods of screening for modulators of the structure, expression, and/or activity of such polypeptides and complexes.

The invention discloses an oxidative damage DNA detection method, and relates to the technical field of DNA oxidative damage detection. The method comprises (a) obtaining of DNA containing 3 ', 5'-phosphate group nucleotide voi, to be more specific, adding a DNA repair enzyme for recognition and cutting of oxidized DNA bases; (b) introduction of hydroxyl into 3 ', 5' site, to be more specific, adding alkaline phosphatase for dephosphorylation to obtain the DNA containing 3 ', 5'-hydroxyl group nucleotide voids; (c) introduction of a fluorescent marker, to be more specific, adding DNA polymerase I and the fluorescent marker to obtain fluorescence-labeled DNA; (d) formation of a PFP-DNA complex, to be more specific, adding PFP to obtain the PFP-DNA complex; and (e) oxidative damage DNA detection, to be more specific, detecting damage DNA by FRET. The method alleviates the disadvantages of tedious steps, low sensitivity and low selectivity of DNA damage detection in the prior art. The method has the advantages of high sensitivity, strong specificity and high accuracy.

The invention discloses an efficient clustered regularly interspaced short palindromic repeats ribonucleoprotein (CRISPR RNP) and donor DNA co-location mediated gene insertion or replacement method and application thereof. The method comprises the following steps: (1) biotin labeling is performed on donor DNA to obtain biotin-labeled donor DNA; (2) fusion protein of Cas9 protein and monovalent streptavidin, sgRNA and the biotin-labeled donor DNA are evenly mixed and undergo standing to obtain a CRISPR RNP-donor DNA complex; and (3) cell nucleus transformation is performed on the CRISPR RNP-donor DNA complex to realize gene insertion or replacement. According to the method, by utilizing the characteristic that the fusion protein can be combined with the biotin-labeled donor DNA, the CRISPRRNP and the donor DNA appear at a target locus together, and precise insertion of the donor DNA at the target locus or accurate replacement of a gene at the target locus is realized; and the method issuitable for the aspect of crop and livestock breeding.

Disclosed is a process for preparing nanometer particles of galactose hydroxyapatite-polylysine which comprises, rinshing hydroxyapatite nano granules with water, centrifuging and collecting deposition, vacuum drying, grinding, suspending hydroxyapatite nano particle powder deposition into water, carrying out ultrasonic oscillation, charging cerebrose polylysine solution, mixing and stirring, centrifuging to remove the supernatant fluid, suspending the deposition into deionized water.